![Andrew J. Sonderfan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Andrew J.
Sonderfan worked as a Director-Toxicology & Product Safety at Biochem Pharma, Inc. from 2000 to 2001.
He then worked as a Senior Director-Toxicology & Safety Pharmacology at Enanta Pharmaceuticals, Inc. After that, he worked as a Vice President-Preclinical Safety Assessment at Synta Pharmaceuticals Corp.
from 2006 to 2011.
Finally, he worked as a Vice President-Toxicology & Early Development at Lysosomal Therapeutics, Inc. Dr. Sonderfan holds a doctorate degree from the University of Kansas and an undergraduate degree from the University of the Sciences in Philadelphia.
Former positions of Andrew J. Sonderfan
Companies | Position | End |
---|---|---|
Biochem Pharma, Inc.
![]() Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Corporate Officer/Principal | 2000-12-31 |
Lysosomal Therapeutics, Inc.
![]() Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
ENANTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Synta Pharmaceuticals Corp.
![]() Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Training of Andrew J. Sonderfan
University of the Sciences in Philadelphia | Undergraduate Degree |
University of Kansas | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ENANTA PHARMACEUTICALS, INC. | Health Technology |
Private companies | 3 |
---|---|
Synta Pharmaceuticals Corp.
![]() Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Biochem Pharma, Inc.
![]() Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Health Technology |
Lysosomal Therapeutics, Inc.
![]() Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Andrew J. Sonderfan